Xcout Intel
MaaT Pharma competitors & alternatives
The 12 closest competitors and alternatives to MaaT Pharma among biotech companies — ranked by similarity to what MaaT Pharma actually does, not by market-cap band.
Subscribe to see MaaT Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About MaaT Pharma
MaaT Pharma is a clinical-stage biotechnology company that develops microbiome-based therapeutics to improve treatment outcomes and survival rates for cancer patients. The company focuses on restoring microbiome function to address life-threatening diseases using a full ecosystem approach and AI-powered drug development.
MaaT Pharma at a glance
MaaT Pharma is a biotech company headquartered in France. Xcout tracks 12 named people at MaaT Pharma, including ERIC SOYER (Chief Financial Officer).
MaaT Pharma leadership
- ERIC SOYERChief Financial Officer
- Carole SchwintnerChief Technology Officer
- Emilie PlantamuraDeputy Chief Medical Officer
- Frédéric FasanoChief Strategy & Corporate Development Officer
- Sheri SimmonsActing Chief Scientific Officer
- Hervé AffagardCEO and co-founder
6 more named people on record for MaaT Pharma, with roles, board committees and tenure — see the full roster →
Top 12 MaaT Pharma competitors
Ranked by semantic similarity — how close each company is to MaaT Pharma by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
T3 Pharmaceuticals AG is a biotechnology company that develops a proprietary technology platform utilizing bacteria to deliver targeted therapies. The company focuses on advancing a pipeline of Immuno-Oncology products designed to treat cancer patients.
Biotechnology
Exeliom Biosciences is a clinical-stage biopharmaceutical company headquartered in France that develops novel therapeutic approaches harnessing microbiome-host interactions.
Biotechnology
ME Therapeutics Holdings Inc. is a clinical-stage biotechnology company that discovers and develops immuno-oncology therapeutics designed to reprogram immune cells in vivo. Its pipeline aims to activate the body's immune system to recognize and fight cancer cells.
Biotechnology
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Biotechnology
Laguna Pharmaceuticals is a biotechnology company developing precision microbial immunotherapy platforms to treat various cancers, including high-risk leukemias and soft-tissue sarcomas. The company utilizes engineered, highly attenuated microbial vectors to activate and expand innate T cells directly within the body, aiming to overcome immune evasion by tumors.
Biotechnology
Surface Oncology is a clinical-stage biotechnology company focused on developing immunotherapies that target the tumor microenvironment and enhance anti-tumor immune responses. Its programs are intended for cancer patients and are developed for use by oncology physicians and healthcare systems, with potential pharmaceutical partnerships.
Biotechnology
Affimed Therapeutics is a biotechnology company focused on developing cancer immunotherapies that recruit and activate innate immune cells, particularly natural killer (NK) cells, to attack tumor cells. Its investigational products are intended for oncology patients and are developed for use by cancer-care providers.
Biotechnology
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Biotechnology
OverT Bio, Inc. is a New York-based biotechnology company that pioneers next-generation cellular therapies and biologics at scale. The company focuses on developing effective and safe cellular treatments for solid tumors.
Biotechnology (Microbiome Therapeutics)
Genome & Company is a global biopharmaceutical company that focuses on developing microbiome pharmaceuticals, consumer products, and novel immune checkpoint inhibitors. The company's expertise spans drug R&D, clinical development, regulatory affairs, and intellectual property.
Biotechnology
Federation Bio is a U.S. biotechnology company developing live biotherapeutic products based on defined microbial communities to treat diseases. Its work has focused on microbiome-based therapies for metabolic and other serious disorders, serving patients with conditions that may benefit from engineered microbial consortia.
Biotechnology
BiomeBank develops and commercializes microbiome therapeutics designed to restore gut ecological complexity and treat human diseases. The company offers regulated donor-derived therapies, such as BIOMICTRA for recurrent Clostridioides difficile infections, and is advancing a pipeline of next-generation co-cultured microbial products for conditions spanning immunology, metabolism, and oncology. It serves medical practitioners and patients by providing clinically informed gut health treatments.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of MaaT Pharma and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for MaaT Pharmaand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →